Progress in determining the causes and treatment of multiple sclerosis (original) (raw)

• Risch, N. & Merikangas, K. The future of genetic studies of complex human diseases. Science 273, 1516–1517 (1996).
  Article ADS CAS PubMed Google Scholar
• Weinshenker, B. G. et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112, 133–146 (1989).
  Article PubMed Google Scholar
• Weinshenker, B. & Miller, D. in Frontiers in Multiple Sclerosis (eds Siva, A., Kesselring, J. & Thompson, A.) (Dunitz, London, 1998).
  Google Scholar
• Hohlfeld, R. Biotechnological agents for the immunotherapy of multiple sclerosis, principles, problems and perspectives. Brain 120, 865–916 (1997).
  Article PubMed Google Scholar
• Noseworthy, J. MS clinical trials: old and new challenges. Semin. Neurol. 18, 377–388 (1998).
  Article CAS PubMed Google Scholar
• Cook, S., Rohowsky-Kochan, C., Bansil, S. & Dowling, P. Evidence for multiple sclerosis as an infectious disease. Acta Neurol. Scand. 161, 34–42 (1996).
  Google Scholar
• Kurtzke, J. F. Epidemiologic evidence for multiple sclerosis as an infection. Clin. Microbiol. Rev. 6, 382–427 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Ebers, G. C. et al. A population-based study of multiple sclerosis in twins. N. Engl. J. Med. 315, 1638–1642 (1986).
  Article CAS PubMed Google Scholar
• Sibley, W. A., Bamford, C. R. & Clark, K. Clinical viral infections and multiple sclerosis. Lancet 1, 1313–1315 (1985).
  Article CAS PubMed Google Scholar
• Herndon, R. Herpesviruses in multiple sclerosis. Arch. Neurol. 53, 123–124 (1996).
  Article CAS PubMed Google Scholar
• Challoner, P. et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc. Natl Acad. Sci. USA 92, 7440–7444 (1995).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Liedtke, W., Malessa, R., Faustmann, P. & Eis-Hubinger, A. Human herpesvirus 6 polymerase chain reaction findings in human immunodeficiency virus associated neurological disease and multiple sclerosis. J. Neurovirol. 1, 253–258 (1995).
  Article CAS PubMed Google Scholar
• Soldan, S. et al. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nature Med. 3, 1394–1397 (1997).
  Article CAS PubMed Google Scholar
• Merelli, E. et al. Human herpes virus 6 and human herpes virus 8 DNA sequences in brains of multiple sclerosis patients, normal adults, and children. J. Neurol. 244, 450–454 (1997).
  Article CAS PubMed Google Scholar
• Steinman, L. & Oldstone, M. More mayhem from molecular mimics. Nature Med. 3, 1321–1322 (1997).
  Article CAS PubMed Google Scholar
• Mason, D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. Today 19, 395–404 (1998).
  Article CAS PubMed Google Scholar
• Sanders, V. et al. Herpes simplex virus in postmortem multiple sclerosis brain tissue. Arch. Neurol. 53, 125–133 (1996).
  Article CAS PubMed Google Scholar
• Sanders, V., Felisan, S., Waddell, A. & Tourtellotte, W. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J. Neurovirol. 2, 249–258 (1996).
  Article CAS PubMed Google Scholar
• Mayne, M. et al. Infrequent detection of human herpesvirus 6 DNA in peripheral blood mononuclear cells from multiple sclerosis patients. Ann. Neurol. 44, 391–394 (1998).
  Article CAS PubMed Google Scholar
• van Noort, J. et al. The small heat-shock protein αβ-crystallin as candidate autoantigen in multiple sclerosis. Nature 375, 798–801 (1995).
  Article ADS CAS PubMed Google Scholar
• Compston, A. Genetic epidemiology of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 62, 553–561 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Sadovnick, A., Dyment, D. & Ebers, G. Genetic epidemiology of multiple sclerosis. Epidemiol. Rev. 19, 99–106 (1997).
  Article CAS PubMed Google Scholar
• Bulman, D. & Ebers, G. The geography of multiple sclerosis reflects genetic susceptibility. J. Trop. Geogr. Neurol. 2, 66–72 (1992).
  Google Scholar
• Dyment, D., Sadovnick, A. & Ebers, G. Genetics of multiple sclerosis. Hum. Mol. Genet. 6, 1693–1698 (1997). [Published erratum appears in Hum. Mol. Genet. 6,, 2189 (1997).]
  Article CAS PubMed Google Scholar
• Little, C. A possible Mendelian explanation for a type of inheritance apparently non-Mendelian in nature. Science 40, 904–906 (1917).
  Article ADS Google Scholar
• Sadovnick, A., Ebers, G., Dyment, D., Risch, N. and the Canadian Collaborative Study Group. Evidence for genetic basis of multiple sclerosis. Lancet 347, 1728–1730 (1996).
  Article CAS PubMed Google Scholar
• Ebers, G., Sadovnick, A., Risch, N. and the Canadian Collaborative Study Group. A genetic basis for familial aggregation in multiple sclerosis. Nature 377, 150–151 (1995).
  Article ADS CAS PubMed Google Scholar
• Waksman, B. More genes versus environment. Nature 377, 105–106 (1995).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Farrall, M. Mapping genetic susceptibility to multiple sclerosis. Lancet 348, 1674–1675 (1996).
  Article CAS PubMed Google Scholar
• Sawcer, S., Goodfellow, P. & Compston, A. The genetic analysis of multiple sclerosis. Trends Genet. 13, 234–239 (1997).
  Article CAS PubMed Google Scholar
• Zhang, H., Zhao, H. & Merikangas, K. Strategies to identify genes for complex diseases. Ann. Med. 29, 493–498 (1997).
  Article CAS PubMed Google Scholar
• Risch, N. Assessing the role of HLA-linked and unlinked determinants of disease. Am. J. Hum. Genet. 40, 1–14 (1987).
  CAS PubMed PubMed Central Google Scholar
• Haines, J. et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. Hum. Mol. Genet. 7, 1229–1234 (1998).
  Article CAS PubMed Google Scholar
• Sawcer, S. et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nature Genet. 13, 464–468 (1996).
  Article CAS PubMed Google Scholar
• Haines, J. et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. Nature Genet. 13, 469–471 (1996).
  Article CAS PubMed Google Scholar
• Ebers, G. et al. A full genome search in multiple sclerosis. Nature Genet. 13, 472–476 (1996).
  Article CAS PubMed Google Scholar
• Bell, J. & Lathrop, G. Multiple loci for multiple sclerosis. Nature Genet. 13, 377–378 (1996).
  Article CAS PubMed Google Scholar
• Kuokkanen, S. et al. A putative vulnerability locus to multiple sclerosis maps to 5p14-p12 in a region syntenic to the murine locus Eae2. Nature Genet. 13, 477–480 (1996).
  Article CAS PubMed Google Scholar
• Kuokkanen, S. et al. Genomewide scan of multiple sclerosis in Finnish multiplex families. Am. J. Hum. Genet. 61, 1379–1387 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Lucchinetti, C. F., Bruck, W., Rodriguez, M. & Lassmann, H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 6, 259–274 (1996).
  Article CAS PubMed Google Scholar
• Storch, M. K. et al. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 43, 465–471 (1998).
  Article CAS PubMed Google Scholar
• Compston, A. Remyelination in multiple sclerosis: a challenge for therapy. The 1996 European Charcot Foundation Lecture. Mult. Scler. 3, 51–70 (1997).
  Article CAS PubMed Google Scholar
• Trapp, B. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278–285 (1998).
  Article CAS PubMed Google Scholar
• Wolinsky, J. S., Narayana, P. A. & Fenstermacher, M. J. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 40, 1764–1769 (1990).
  Article CAS PubMed Google Scholar
• Arnold, D. L., Matthews, P. M., Francis, G. & Antel, J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn. Reson. Med. 14, 154–159 (1990).
  Article CAS PubMed Google Scholar
• Arnold, D. L., Matthews, P. M., Francis, G. S., O' Connor, J. & Antel, J. P. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann. Neurol. 31, 235–241 (1992).
  Article CAS PubMed Google Scholar
• Davie, C. et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 117, 49–58 (1994).
  Article PubMed Google Scholar
• Matthews, P. et al. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin. Neurol. 18, 327–336 (1998).
  Article CAS PubMed Google Scholar
• Losseff, N. et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119, 2009–2019 (1996).
  Article PubMed Google Scholar
• Losseff, N. et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119, 701–708 (1996).
  Article PubMed Google Scholar
• Waxman, S. Demyelinating diseases — new pathological insights, new therapeutic targets. N. Engl. J. Med. 338, 323–325 (1998).
  CAS PubMed Google Scholar
• Bunge, M. B., Bunge, R. P. & Ris, H. Ultrastructural study of remyelination in an experimental lesion in the adult cat spinal cord. J. Biophys. Biochem. Cytol. 10, 67–94 (1961).
  Article CAS PubMed PubMed Central Google Scholar
• Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R. & Cho, E.-S. Multiple sclerosis: remyelination of nascent lesions. Ann. Neurol. 33, 137–151 (1993).
  Article CAS PubMed Google Scholar
• Zajicek, J. & Compston, A. Mechanisms of damage and repair in multiple sclerosis — a review. Mult. Scler. 1, 61–72 (1995).
  Article CAS PubMed Google Scholar
• Compston, A. Future options for therapies to limit damage and enhance recovery. Semin. Neurol. 18, 405–413 (1998).
  Article CAS PubMed Google Scholar
• Scolding, N. et al. A proliferative adult human oligodendrocyte progenitor. NeuroReport 6, 441–445 (1995).
  Article CAS PubMed Google Scholar
• Rodriguez, M. & Lennon, V. A. Immunoglobulins promote remyelination in the central nervous system. Ann. Neurol. 27, 12–17 (1990).
  Article CAS PubMed Google Scholar
• Noseworthy, J., O'Brien, P., van Engelen, B. & Rodriguez, M. Intravenous immunoglobulin therapy in multiple sclerosis: progress from the Theiler's virus model to a randomized, double-blinded, placebo-controlled clinical trial. J. Neurol. Neurosurg. Psychiatry 57(Suppl.), 11–14 (1994).
  Article PubMed PubMed Central Google Scholar
• Noseworthy, J., Weinshenker, B. & O'Brien, P. Intravenous immunoglobulin (IVIg) does not reverse recently acquired, apparently permanent weakness in multiple sclerosis (MS). Ann. Neurol. 42, A421 (1997).
  Google Scholar
• Noseworthy, J. et al. Immunoglobulin administration (IVIg) does not reverse visual acuity loss in long-standing optic neuritis associated with multiple sclerosis. Ann. Neurol. 44, A504 (1998).
  Google Scholar
• Bostock, H. & Sears, T. The internodal axon membrane: electrical excitability and continuous conduction in segmental demyelination. J. Physiol. (Lond.) 280, 273–301 (1978).
  Article CAS PubMed Central Google Scholar
• Waxman, S. in Brain Plasticity, Advances in Neurology (eds Freund, H. J., Sabel, B. A. & Witte, O. W.) 109–120 (Lippincott-Raven, Philadelphia, 1997).
  Google Scholar
• Rivera-Quinones, C. et al. Absence of neurological deficits following extensive demyelination in a class 1-deficient murine model of multiple sclerosis. Nature Med. 4, 187–193 (1998).
  Article CAS PubMed Google Scholar
• Ludwin, S. & Johnson, E. Evidence of a “dying back” gliopathy in demyelinating disease. Ann. Neurol. 9, 301–305 (1981).
  Article CAS PubMed Google Scholar
• Rodriguez, M. Virus-induced demyelination in mice: “dying back” of oligodendrocytes. Mayo Clin. Proc. 60, 433–438 (1985).
  Article CAS PubMed Google Scholar
• Ferguson, B., Matyszak, M., Esiri, M. & Petty, V. Axonal damage in acute multiple sclerosis lesions. Brain 120, 393–399 (1997).
  Article PubMed Google Scholar
• Miller, D., Grossman, R., Reingold, S. & McFarland, H. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 121, 3–24 (1998).
  Article PubMed Google Scholar
• van Walderveen, M. A. A. et al. Correlating MR imaging and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short TR/TE (“T1-weighted”) spin-echo images. Neurology 45, 1684–1690 (1995).
  Article CAS PubMed Google Scholar
• Gass, A. et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann. Neurol. 36, 62–67 (1994).
  Article CAS PubMed Google Scholar
• Kidd, D. et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 60, 15–19 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Miller, D. Multiple sclerosis: use of MRI in evaluating new therapies. Semin. Neurol. 18, 317–325 (1998).
  Article CAS PubMed Google Scholar
• De Stefano, N. et al. Axonal damage correlated with disability in patients with relapsing-remitting multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy study. Brain 121, 1469–1477 (1998).
  Article PubMed Google Scholar
• Filippi, M., Rocca, M., Martino, G., Horsfield, M. & Comi, G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann. Neurol. 43, 809–814 (1998).
  Article CAS PubMed Google Scholar
• Goodkin, D. et al. A serial study of new MS lesions and the white matter from which they arise. Neurology 51, 1689–1697 (1998).
  Article CAS PubMed Google Scholar
• Kidd, D. et al. Central motor conduction time in progressive multiple sclerosis: correlations with MRI and disease activity. Brain 121, 1109–1116 (1998).
  Article PubMed Google Scholar
• Noseworthy, J. H., Vandervoort, M. K., Hopkins, M. & Ebers, G. C. A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop. Neurology 39, 977–981 (1989).
  Article CAS PubMed Google Scholar
• Noseworthy, J. H., Vandervoort, M. K., Wong, C. J. & Ebers, G. C. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology 40, 971–975 (1990).
  Article CAS PubMed Google Scholar
• Noseworthy, J. H. et al. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 44, 16–20 (1994).
  Article CAS PubMed Google Scholar
• Petkau, J. Statistical methods for evaluating multiple sclerosis therapies. Semin. Neurol. 18, 351–375 (1998).
  Article CAS PubMed Google Scholar
• Stone, L. et al. Characterization of MRI response to treatment with interferon beta-1b: contrastenhancing MRI lesion frequency as a primary outcome measure. Neurology 49, 862–869 (1997).
  Article CAS PubMed Google Scholar
• Calabresi, P., Stone, L., Bash, C., Frank, J. & McFarland, H. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 48, 1446–1448 (1997).
  Article CAS PubMed Google Scholar
• Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 662–667 (1993).
  Article CAS PubMed Google Scholar
• The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon b-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 45, 1277–1285 (1995).
• Simon, J. et al. Magnetic resonance studies of intramuscular interferon b-1a for relapsing multiple sclerosis. Neurology 43, 79–87 (1998).
  CAS Google Scholar
• PRISMS (Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) Study Group. Randomised double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Lancet 352, 1498–1504 (1998).
• Kappos, L. and the European Study Group on Interferon beta-1b in secondary-progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352, 1491–1497 (1998).
  Article CAS Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 655–661 (1993).
• Jacobs, L. D. et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39, 285–294 (1996).
  Article CAS PubMed Google Scholar
• Rudick, R. et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 49, 358–363 (1997).
  Article CAS PubMed Google Scholar
• Johnson, K. P. et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45, 1268–1276 (1995).
  Article CAS PubMed Google Scholar
• Johnson, K. et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 50, 701–708 (1998).
  Article CAS PubMed Google Scholar
• Fazekas, F., Deisenhammer, F., Strasser-Fuchs, S., Nahler, G., Mamoli, B. and the Austrian Immunoglobulin in MS Study Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 349, 589–593 (1997).
  Article CAS PubMed Google Scholar
• Achiron, A. et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 50, 398–402 (1998).
  Article CAS PubMed Google Scholar
• Sorensen, P. et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50, 1273–1281 (1998).
  Article CAS PubMed Google Scholar
• van den Noort, S. et al. National MS Society (NMSS): Disease Management Consensus Statement (National MS Society, New York, 1998).
  Google Scholar
• Weinshenker, B. G. et al. The natural history of multiple sclerosis: a geographically based study. II. Predictive value of the early clinical course. Brain 112, 1419–1428 (1989).
  Article PubMed Google Scholar
• Noseworthy, J. in A Problem-oriented Approach to Management and Treatment of Multiple Sclerosis. (eds Thompson, A., Polman, C. & Hohlfeld, R.) 177–193 (Dunitz, London, 1997).
  Google Scholar
• Noseworthy, J., O'Brien, P. and the Mayo Clinic-Canadian Cooperative MS Study Group. The Mayo Clinic Canadian Cooperative Trial of Sulfasalazine in active multiple sclerosis. Neurology 51, 1342–1352 (1998).
  Article CAS PubMed Google Scholar
• van Noort, J. Multiple sclerosis: an altered immune response or an altered stress response? J. Mol. Med. 74, 285–296 (1996).
  Article CAS PubMed Google Scholar
• Murray, P. et al. Perforin-dependent neurologic injury in a viral model of multiple sclerosis. J. Neurosci. 18, 7306–7314 (1998).
  Article CAS PubMed PubMed Central Google Scholar